{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:53:41Z","timestamp":1786985621075,"version":"build-2736575974"},"reference-count":170,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.canlet.2024.217119","type":"journal-article","created":{"date-parts":[[2024,7,14]],"date-time":"2024-07-14T01:13:22Z","timestamp":1720919602000},"page":"217119","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["\u201cCyclophosphamide and analogues; a matter of dose and schedule for dual anticancer activities\u201d"],"prefix":"10.1016","volume":"598","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2346-9608","authenticated-orcid":false,"given":"Julia","family":"Delahousse","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Molina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Paci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.canlet.2024.217119_bib1","doi-asserted-by":"crossref","first-page":"4604","DOI":"10.1128\/MCB.16.9.4604","article-title":"Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1","volume":"16","author":"Forsythe","year":"1996","journal-title":"Mol. Cell Biol."},{"issue":"7","key":"10.1016\/j.canlet.2024.217119_bib2","first-page":"1878","article-title":"Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer","volume":"60","author":"Browder","year":"2000","journal-title":"Cancer Res."},{"issue":"8","key":"10.1016\/j.canlet.2024.217119_bib3","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1093\/annonc\/mdu191","article-title":"Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients","volume":"25","author":"Ali","year":"2014","journal-title":"Ann. Oncol."},{"issue":"1\u20132","key":"10.1016\/j.canlet.2024.217119_bib4","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jneuroim.2013.08.013","article-title":"Elevated CD3+ and CD8+ tumor-infiltrating immune cells correlate with prolonged survival in glioblastoma patients despite integrated immunosuppressive mechanisms in the tumor microenvironment and at the systemic level","volume":"264","author":"Kmiecik","year":"2013","journal-title":"J. Neuroimmunol."},{"issue":"1","key":"10.1016\/j.canlet.2024.217119_bib5","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1158\/0008-5472.CAN-06-3388","article-title":"High number of intraepithelial CD8+ tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer","volume":"67","author":"Piersma","year":"2007","journal-title":"Cancer Res."},{"issue":"9","key":"10.1016\/j.canlet.2024.217119_bib6","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/nm1093","article-title":"Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival","volume":"10","author":"Curiel","year":"2004","journal-title":"Nat. Med."},{"issue":"7","key":"10.1016\/j.canlet.2024.217119_bib7","first-page":"1781","article-title":"Presence of FOXP3(+)Treg cells is correlated with colorectal cancer progression","volume":"7","author":"Liu","year":"2014","journal-title":"Int. J. Clin. Exp. Med."},{"issue":"12","key":"10.1016\/j.canlet.2024.217119_bib8","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1038\/modpathol.2008.160","article-title":"Immunosuppressive regulatory T cells are associated with aggressive breast cancer phenotypes: a potential therapeutic target","volume":"21","author":"Bohling","year":"2008","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.canlet.2024.217119_bib9","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1146\/annurev.immunol.021908.132710","article-title":"IL-17 and Th17 cells","volume":"27","author":"Korn","year":"2009","journal-title":"Annu. Rev. Immunol."},{"issue":"9","key":"10.1016\/j.canlet.2024.217119_bib10","doi-asserted-by":"crossref","first-page":"8358","DOI":"10.3390\/ijms24098358","article-title":"Biologic mechanisms of macrophage phenotypes responding to infection and the novel therapies to moderate inflammation","volume":"24","author":"Ni","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"2\u20134","key":"10.1016\/j.canlet.2024.217119_bib11","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0161-5890(03)00109-3","article-title":"\u201cEat me\u201d and \u201cdon't eat me\u201d signals govern the innate immune response and tissue repair in the CNS: emphasis on the critical role of the complement system","volume":"40","author":"Elward","year":"2003","journal-title":"Mol. Immunol."},{"issue":"2","key":"10.1016\/j.canlet.2024.217119_bib12","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1021\/jm501224x","article-title":"Preactivated oxazaphosphorines designed for isophosphoramide mustard delivery as bulk form or nanoassemblies: synthesis and proof of concept","volume":"58","author":"Skarbek","year":"2015","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.canlet.2024.217119_bib13","first-page":"65","article-title":"DOSE-RESPONSE relationships for agents inhibiting the immune response","volume":"7","author":"Berenbaum","year":"1964","journal-title":"Immunology"},{"issue":"1","key":"10.1016\/j.canlet.2024.217119_bib14","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/art.1780160106","article-title":"Immune response of patients with rheumatoid arthritis during cyclophosphamide treatment","volume":"16","author":"Curtis","year":"1973","journal-title":"Arthritis Rheum."},{"issue":"2","key":"10.1016\/j.canlet.2024.217119_bib15","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/ijc.2910110213","article-title":"Contribution of host immunity to cyclophosphamide therapy of a chemically-induced murine sarcoma","volume":"11","author":"Moore","year":"1973","journal-title":"Int. J. Cancer"},{"issue":"4","key":"10.1016\/j.canlet.2024.217119_bib16","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1002\/ijc.2910130417","article-title":"Effects of cyclophosphamide on immunity against chemically-induced syngeneic murine sarcomas","volume":"13","author":"Steele","year":"1974","journal-title":"Int. J. Cancer"},{"issue":"5","key":"10.1016\/j.canlet.2024.217119_bib17","first-page":"939","article-title":"Reversal by cyclophosphamide of tolerance in contact sensitization. Tolerance induced by prior feeding with DNCB","volume":"28","author":"Polak","year":"1975","journal-title":"Immunology"},{"issue":"7","key":"10.1016\/j.canlet.2024.217119_bib18","first-page":"3112","article-title":"Some advantages of curing mice bearing a large subcutaneous MOPC-315 tumor with a low dose rather than a high dose of cyclophosphamide","volume":"43","author":"Mokyr","year":"1983","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.canlet.2024.217119_bib19","first-page":"161","article-title":"Local administration of cytostatic drug 4-hydroperoxy-cyclophosphamide (4-HPCY) facilitates cell-mediated immune reactions","volume":"58","author":"Boerrigter","year":"1984","journal-title":"Clin. Exp. Immunol."},{"issue":"1","key":"10.1016\/j.canlet.2024.217119_bib20","first-page":"41","article-title":"Enhancement of in vivo and in vitro murine immune responses by the cyclophosphamide metabolite acrolein","volume":"48","author":"Kawabata","year":"1988","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.canlet.2024.217119_bib21","first-page":"39","article-title":"[Long-term changes in the immune system following cytostatic polychemotherapy in patients with testicular tumors in remission]","volume":"12","author":"Wegener-H\u00f6pfner","year":"1984","journal-title":"Immun. Infekt."},{"issue":"3","key":"10.1016\/j.canlet.2024.217119_bib22","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/0098-2997(93)90016-7","article-title":"Ifosfamide induced stress response in human lymphocytes","volume":"14","author":"Issels","year":"1993","journal-title":"Mol. Aspect. Med."},{"issue":"Suppl 2","key":"10.1016\/j.canlet.2024.217119_bib23","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1159\/000073353","article-title":"Ifosfamide and cyclophosphamide: effects on immunosurveillance","volume":"65","author":"Binotto","year":"2003","journal-title":"Oncology"},{"issue":"8","key":"10.1016\/j.canlet.2024.217119_bib24","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1182\/blood.V85.8.2124.bloodjournal8582124","article-title":"Differential effects of ifosfamide on the capacity of cytotoxic T lymphocytes and natural killer cells to lyse their target cells correlate with intracellular glutathione levels","volume":"85","author":"Multhoff","year":"1995","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.canlet.2024.217119_bib25","doi-asserted-by":"crossref","first-page":"3668","DOI":"10.1182\/blood-2003-05-1408","article-title":"Ifosfamide impairs the allostimulatory capacity of human dendritic cells by intracellular glutathione depletion","volume":"102","author":"Kuppner","year":"2003","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.canlet.2024.217119_bib26","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/j.1365-2249.2008.03708.x","article-title":"Differential effects of ifosfamide on dendritic cell-mediated stimulation of T cell interleukin-2 production, natural killer cell cytotoxicity and interferon-\u03b3 production","volume":"153","author":"Kuppner","year":"2008","journal-title":"Clin. Exp. Immunol."},{"issue":"2","key":"10.1016\/j.canlet.2024.217119_bib27","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000916","article-title":"Oxazaphosphorines combined with immune checkpoint blockers: dose-dependent tuning between immune and cytotoxic effects","volume":"8","author":"Delahousse","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"7_Supplement","key":"10.1016\/j.canlet.2024.217119_bib28","first-page":"15","article-title":"Metronomic scheduling of trofosfamide chemotherapy in human NSCLC xenografts highly increases therapeutic efficacy compared to conventional scheduling by inhibition of angiogenesis","volume":"64","author":"Klink","year":"2004","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.canlet.2024.217119_bib29","first-page":"831","article-title":"Low-dose oral metronomic chemotherapy prevents mobilization of endothelial progenitor cells into the blood of cancer patients","volume":"22","author":"Stoelting","year":"2008","journal-title":"In Vivo"},{"issue":"1","key":"10.1016\/j.canlet.2024.217119_bib30","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nm.3045","article-title":"Dual role of immunomodulation by anticancer chemotherapy","volume":"19","author":"Shurin","year":"2013","journal-title":"Nat. Med."},{"issue":"25","key":"10.1016\/j.canlet.2024.217119_bib31","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1056\/NEJMoa2215943","article-title":"Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis","volume":"388","author":"Bola\u00f1os-Meade","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.canlet.2024.217119_bib32","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1016\/j.ymthe.2018.05.018","article-title":"Autologous CD19-targeted CAR T cells in patients with residual CLL following initial purine analog-based therapy","volume":"26","author":"Geyer","year":"2018","journal-title":"Mol. Ther."},{"issue":"303","key":"10.1016\/j.canlet.2024.217119_bib33","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aac5415","article-title":"Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia","volume":"7","author":"Porter","year":"2015","journal-title":"Sci. Transl. Med."},{"issue":"17","key":"10.1016\/j.canlet.2024.217119_bib34","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1182\/blood-2018-11-887067","article-title":"The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells","volume":"133","author":"Hirayama","year":"2019","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.canlet.2024.217119_bib35","first-page":"4342","article-title":"Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells","volume":"63","author":"Bertolini","year":"2003","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.canlet.2024.217119_bib36","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1158\/0008-5472.CAN-03-3126","article-title":"Thrombospondin-1 associated with tumor microenvironment contributes to low-dose cyclophosphamide-mediated endothelial cell apoptosis and tumor growth suppression","volume":"64","author":"Hamano","year":"2004","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.canlet.2024.217119_bib37","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1158\/0008-5472.CAN-10-2788","article-title":"Cyclophosphamide synergizes with type I interferons through systemic dendritic cell reactivation and induction of immunogenic tumor apoptosis","volume":"71","author":"Schiavoni","year":"2011","journal-title":"Cancer Res."},{"issue":"23","key":"10.1016\/j.canlet.2024.217119_bib38","doi-asserted-by":"crossref","first-page":"5034","DOI":"10.1158\/0008-5472.CAN-14-3098","article-title":"Chemotherapy induces programmed cell death-ligand 1 overexpression via the nuclear factor- B to foster an immunosuppressive tumor microenvironment in ovarian cancer","volume":"75","author":"Peng","year":"2015","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.canlet.2024.217119_bib39","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.2214\/AJR.07.4060","article-title":"In vivo bioluminescence imaging monitoring of hypoxia-inducible factor 1 alpha, a promoter that protects cells, in response to chemotherapy","volume":"191","author":"Viola","year":"2008","journal-title":"AJR Am. J. Roentgenol."},{"issue":"7","key":"10.1016\/j.canlet.2024.217119_bib40","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1182\/blood-2004-06-2410","article-title":"Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide","volume":"105","author":"Lutsiak","year":"2005","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.canlet.2024.217119_bib41","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/eji.200324181","article-title":"CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative","volume":"34","author":"Ghiringhelli","year":"2004","journal-title":"Eur. J. Immunol."},{"issue":"5","key":"10.1016\/j.canlet.2024.217119_bib42","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s00262-006-0225-8","article-title":"Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients","volume":"56","author":"Ghiringhelli","year":"2007","journal-title":"Cancer Immunol. Immunother."},{"issue":"1","key":"10.1016\/j.canlet.2024.217119_bib43","first-page":"87","article-title":"Cyclophosphamide (Cy)-facilitated adoptive immunotherapy of a Cy-resistant tumour. Evidence that Cy permits the expression of adoptive T-cell mediated immunity by removing suppressor T cells rather than by reducing tumour burden","volume":"65","author":"Awwad","year":"1988","journal-title":"Immunology"},{"issue":"12","key":"10.1016\/j.canlet.2024.217119_bib44","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0083384","article-title":"Human CD4+CD25+ regulatory T cells are sensitive to low dose cyclophosphamide: implications for the immune response","volume":"8","author":"Heylmann","year":"2013","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.canlet.2024.217119_bib45","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.humimm.2011.12.020","article-title":"Cyclophosphamide inhibits the generation and function of CD8(+) regulatory T cells","volume":"73","author":"Traverso","year":"2012","journal-title":"Hum. Immunol."},{"issue":"12","key":"10.1016\/j.canlet.2024.217119_bib46","first-page":"3317","article-title":"Effect of low dose cyclophosphamide on the immune system of cancer patients: reduction of T-suppressor function without depletion of the CD8+ subset","volume":"47","author":"Berd","year":"1987","journal-title":"Cancer Res."},{"issue":"12","key":"10.1016\/j.canlet.2024.217119_bib47","doi-asserted-by":"crossref","first-page":"3614","DOI":"10.1002\/eji.201444879","article-title":"Human regulatory T cells lack the cyclophosphamide-extruding transporter ABCB1 and are more susceptible to cyclophosphamide-induced apoptosis","volume":"44","author":"Dimeloe","year":"2014","journal-title":"Eur. J. Immunol."},{"issue":"10","key":"10.1016\/j.canlet.2024.217119_bib48","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1182\/blood.V85.10.2742.bloodjournal85102742","article-title":"Assessment of aldehyde dehydrogenase in viable cells","volume":"85","author":"Jones","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2024.217119_bib49","doi-asserted-by":"crossref","first-page":"222","DOI":"10.3389\/fimmu.2016.00222","article-title":"Molecular mechanisms for cAMP-mediated immunoregulation in T cells - role of anchored protein kinase A signaling units","volume":"7","author":"Wehbi","year":"2016","journal-title":"Front. Immunol."},{"issue":"7130","key":"10.1016\/j.canlet.2024.217119_bib50","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1038\/nature05563","article-title":"Genome-wide analysis of Foxp3 target genes in developing and mature regulatory T cells","volume":"445","author":"Zheng","year":"2007","journal-title":"Nature"},{"issue":"7129","key":"10.1016\/j.canlet.2024.217119_bib51","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/nature05543","article-title":"Foxp3-dependent programme of regulatory T-cell differentiation","volume":"445","author":"Gavin","year":"2007","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.canlet.2024.217119_bib52","doi-asserted-by":"crossref","first-page":"4850","DOI":"10.1158\/0008-5472.CAN-10-0283","article-title":"Selective depletion of CD4+CD25+Foxp3+ regulatory T cells by low-dose cyclophosphamide is explained by reduced intracellular ATP levels","volume":"70","author":"Zhao","year":"2010","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.canlet.2024.217119_bib53","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0960-9822(99)80093-1","article-title":"Identification of a new member of the tumor necrosis factor family and its receptor, a human ortholog of mouse GITR","volume":"9","author":"Gurney","year":"1999","journal-title":"Curr. Biol."},{"issue":"8","key":"10.1016\/j.canlet.2024.217119_bib54","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1007\/s00262-008-0628-9","article-title":"Tumor eradication after cyclophosphamide depends on concurrent depletion of regulatory T cells: a role for cycling TNFR2-expressing effector-suppressor T cells in limiting effective chemotherapy","volume":"58","author":"van der Most","year":"2009","journal-title":"Cancer Immunol. Immunother."},{"issue":"10","key":"10.1016\/j.canlet.2024.217119_bib55","doi-asserted-by":"crossref","first-page":"6467","DOI":"10.4049\/jimmunol.180.10.6467","article-title":"Cutting edge: expression of TNFR2 defines a maximally suppressive subset of mouse CD4+CD25+FoxP3+ T regulatory cells: applicability to tumor-infiltrating T regulatory cells","volume":"180","author":"Chen","year":"2008","journal-title":"J. Immunol."},{"issue":"5","key":"10.1016\/j.canlet.2024.217119_bib56","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.4049\/jimmunol.180.5.2967","article-title":"Expression of ICOS on human melanoma-infiltrating CD4+CD25highFoxp3+ T regulatory cells: implications and impact on tumor-mediated immune suppression","volume":"180","author":"Strauss","year":"2008","journal-title":"J. Immunol."},{"issue":"3","key":"10.1016\/j.canlet.2024.217119_bib57","doi-asserted-by":"crossref","first-page":"957","DOI":"10.3390\/ijms21030957","article-title":"Low dose cyclophosphamide modulates tumor microenvironment by TGF-\u03b2 signaling pathway","volume":"21","author":"Zhong","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.canlet.2024.217119_bib58","first-page":"881","article-title":"The contribution of vascular endothelial growth factor to the induction of regulatory T-cells in malignant effusions","volume":"29","author":"Wada","year":"2009","journal-title":"Anticancer Res."},{"issue":"4","key":"10.1016\/j.canlet.2024.217119_bib59","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/(SICI)1096-9098(199804)67:4<221::AID-JSO3>3.0.CO;2-A","article-title":"Cyclophosphamide given after active specific immunization augments antitumor immunity by modulation of Th1 commitment of CD4+ T cells","volume":"67","author":"Li","year":"1998","journal-title":"J. Surg. Oncol."},{"issue":"11","key":"10.1016\/j.canlet.2024.217119_bib60","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1007\/s00262-001-0237-3","article-title":"Th2\/Th1 switch induced by a single low dose of cyclophosphamide in a rat metastatic lymphoma model","volume":"50","author":"Matar","year":"2002","journal-title":"Cancer Immunol. Immunother."},{"issue":"9","key":"10.1016\/j.canlet.2024.217119_bib61","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.3390\/ijms17091433","article-title":"Targeting the tumor microenvironment: the protumor effects of IL-17 related to cancer type","volume":"17","author":"Fabre","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.canlet.2024.217119_bib62","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/ncomms1524","article-title":"CD91-dependent programming of T-helper cell responses following heat shock protein immunization","volume":"2","author":"Pawaria","year":"2011","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.canlet.2024.217119_bib63","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1158\/0008-5472.CAN-10-1259","article-title":"Cyclophosphamide induces differentiation of Th17 cells in cancer patients","volume":"71","author":"Viaud","year":"2011","journal-title":"Cancer Res."},{"issue":"6161","key":"10.1016\/j.canlet.2024.217119_bib64","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1126\/science.1240537","article-title":"The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide","volume":"342","author":"Viaud","year":"2013","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.canlet.2024.217119_bib65","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1084\/jem.20051511","article-title":"CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner","volume":"202","author":"Ghiringhelli","year":"2005","journal-title":"J. Exp. Med."},{"issue":"12","key":"10.1016\/j.canlet.2024.217119_bib66","doi-asserted-by":"crossref","first-page":"6891","DOI":"10.4049\/jimmunol.171.12.6891","article-title":"Evasion from NK cell immunity by MHC class I chain-related molecules expressing colon adenocarcinoma","volume":"171","author":"Doubrovina","year":"2003","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.canlet.2024.217119_bib67","doi-asserted-by":"crossref","first-page":"277","DOI":"10.4049\/jimmunol.110.1.277","article-title":"Differential effects of cyclophosphamide on the B and T cell compartments of adult mice","volume":"110","author":"Stockman","year":"1973","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.canlet.2024.217119_bib68","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/art.1780180113","article-title":"The effect of cyclophosphamide on B and T lymphocytes in patients with connective tissue diseases","volume":"18","author":"Hurd","year":"1975","journal-title":"Arthritis Rheum."},{"issue":"6","key":"10.1016\/j.canlet.2024.217119_bib69","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.4049\/jimmunol.128.6.2453","article-title":"Suppression of human B lymphocyte function by cyclophosphamide","volume":"128","author":"Cupps","year":"1982","journal-title":"J. Immunol."},{"issue":"4","key":"10.1016\/j.canlet.2024.217119_bib70","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1172\/JCI112922","article-title":"Selective effects of cyclophosphamide therapy on activation, proliferation, and differentiation of human B cells","volume":"79","author":"Zhu","year":"1987","journal-title":"J. Clin. Invest."},{"issue":"3","key":"10.1016\/j.canlet.2024.217119_bib71","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1158\/2159-8290.CD-15-0822","article-title":"Hif1a deletion reveals pro-neoplastic function of B cells in pancreatic neoplasia","volume":"6","author":"Lee","year":"2016","journal-title":"Cancer Discov."},{"issue":"2 Pt 1","key":"10.1016\/j.canlet.2024.217119_bib72","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1158\/1078-0432.CCR-06-1209","article-title":"Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration","volume":"13","author":"Bracci","year":"2007","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.canlet.2024.217119_bib73","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1038\/jid.2012.444","article-title":"Cyclophosphamide promotes chronic inflammation-dependent immunosuppression and prevents antitumor response in melanoma","volume":"133","author":"Sevko","year":"2013","journal-title":"J. Invest. Dermatol."},{"issue":"3","key":"10.1016\/j.canlet.2024.217119_bib74","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/S1734-1140(09)70098-2","article-title":"Influence of cyclophosphamide and its metabolic products on the activity of peritoneal macrophages in mice","volume":"61","author":"Bryniarski","year":"2009","journal-title":"Pharmacol. Rep."},{"issue":"2","key":"10.1016\/j.canlet.2024.217119_bib75","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1097\/01.shk.0000225404.51320.82","article-title":"HMGB1 signals through toll-like receptor (TLR) 4 and TLR2","volume":"26","author":"Yu","year":"2006","journal-title":"Shock"},{"issue":"6","key":"10.1016\/j.canlet.2024.217119_bib76","doi-asserted-by":"crossref","first-page":"3517","DOI":"10.4049\/jimmunol.1003267","article-title":"DNA alkylating therapy induces tumor regression through an HMGB1-mediated activation of innate immunity","volume":"186","author":"Guerriero","year":"2011","journal-title":"J. Immunol."},{"issue":"5","key":"10.1016\/j.canlet.2024.217119_bib77","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1101\/gad.1881410","article-title":"Differential activation and antagonistic function of HIF-{alpha} isoforms in macrophages are essential for NO homeostasis","volume":"24","author":"Takeda","year":"2010","journal-title":"Genes Dev."},{"issue":"2","key":"10.1016\/j.canlet.2024.217119_bib78","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.cellimm.2009.11.011","article-title":"Cyclophosphamide induces bone marrow to yield higher numbers of precursor dendritic cells in vitro capable of functional antigen presentation to T cells in vivo","volume":"261","author":"Salem","year":"2010","journal-title":"Cell. Immunol."},{"issue":"12","key":"10.1016\/j.canlet.2024.217119_bib79","doi-asserted-by":"crossref","first-page":"7506","DOI":"10.4049\/jimmunol.174.12.7506","article-title":"Release of high mobility group box 1 by dendritic cells controls T cell activation via the receptor for advanced glycation end products","volume":"174","author":"Dumitriu","year":"2005","journal-title":"J. Immunol."},{"issue":"6263","key":"10.1016\/j.canlet.2024.217119_bib80","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1126\/science.aad0779","article-title":"Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1","volume":"350","author":"Vacchelli","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.canlet.2024.217119_bib81","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jaut.2017.06.012","article-title":"Regulation of inflammation by members of the formyl-peptide receptor family","volume":"85","author":"Chen","year":"2017","journal-title":"J. Autoimmun."},{"issue":"1","key":"10.1016\/j.canlet.2024.217119_bib82","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s00262-009-0734-3","article-title":"Cyclophosphamide resets dendritic cell homeostasis and enhances antitumor immunity through effects that extend beyond regulatory T cell elimination","volume":"59","author":"Radojcic","year":"2010","journal-title":"Cancer Immunol. Immunother."},{"issue":"22","key":"10.1016\/j.canlet.2024.217119_bib83","doi-asserted-by":"crossref","first-page":"4384","DOI":"10.1182\/blood-2009-11-251231","article-title":"Cyclophosphamide enhances immunity by modulating the balance of dendritic cell subsets in lymphoid organs","volume":"115","author":"Nakahara","year":"2010","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.canlet.2024.217119_bib84","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1016\/j.juro.2007.01.143","article-title":"Low dose metronomic oral cyclophosphamide for hormone resistant prostate cancer: a phase II study","volume":"177","author":"Lord","year":"2007","journal-title":"J. Urol."},{"key":"10.1016\/j.canlet.2024.217119_bib85","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1186\/1471-2407-14-947","article-title":"Metronomic oral cyclophosphamide (MOC) in the salvage therapy of heavily treated recurrent ovarian cancer patients: a retrospective, multicenter study","volume":"14","author":"Ferrandina","year":"2014","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.canlet.2024.217119_bib86","doi-asserted-by":"crossref","first-page":"e154","DOI":"10.1111\/ajco.12074","article-title":"Oral cyclophosphamide in recurrent ovarian cancer","volume":"12","author":"Handolias","year":"2016","journal-title":"Asia Pac. J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2024.217119_bib87","article-title":"Metronomic chemotherapy using oral cyclophosphamide and bevacizumab for recurrent cervical cancer: a multi-institutional retrospective study","volume":"42","author":"Isono-Taniguchi","year":"2022","journal-title":"Gynecol Oncol Rep"},{"issue":"5","key":"10.1016\/j.canlet.2024.217119_bib88","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1179\/joc.2008.20.5.632","article-title":"Bevacizumab in combination with metronomic chemotherapy in patients with anthracycline- and taxane-refractory breast cancer","volume":"20","author":"Garc\u00eda-S\u00e1enz","year":"2008","journal-title":"J. Chemother."},{"issue":"9","key":"10.1016\/j.canlet.2024.217119_bib89","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s12094-008-0254-7","article-title":"Combined oral cyclophosphamide and bevacizumab in heavily pre-treated ovarian cancer","volume":"10","author":"Jurado","year":"2008","journal-title":"Clin. Transl. Oncol."},{"issue":"2","key":"10.1016\/j.canlet.2024.217119_bib90","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.ygyno.2007.07.017","article-title":"Bevacizumab plus cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer","volume":"107","author":"Chura","year":"2007","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.canlet.2024.217119_bib91","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.clbc.2012.03.008","article-title":"Metronomic chemotherapy combined with bevacizumab and erlotinib in patients with metastatic HER2-negative breast cancer: clinical and biological activity","volume":"12","author":"Montagna","year":"2012","journal-title":"Clin. Breast Cancer"},{"issue":"1","key":"10.1016\/j.canlet.2024.217119_bib92","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1186\/s12885-016-2823-y","volume":"16","author":"Rochlitz","year":"2016","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.canlet.2024.217119_bib93","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s10549-023-07167-9","article-title":"A randomized phase II study of metronomic cyclophosphamide and methotrexate (CM) with or without bevacizumab in patients with advanced breast cancer","volume":"204","author":"Mayer","year":"2024","journal-title":"Breast Cancer Res. Treat."},{"issue":"3","key":"10.1016\/j.canlet.2024.217119_bib94","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/ajco.12583","article-title":"Efficacy of metronomic oral cyclophosphamide with low dose dexamethasone and celecoxib in metastatic castration-resistant prostate cancer","volume":"13","author":"Jeong","year":"2017","journal-title":"Asia Pac. J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.canlet.2024.217119_bib95","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1111\/j.1532-5415.2010.02833.x","article-title":"Metronomic cyclophosphamide in elderly patients with advanced, castration-resistant prostate cancer","volume":"58","author":"Fontana","year":"2010","journal-title":"J. Am. Geriatr. Soc."},{"issue":"2","key":"10.1016\/j.canlet.2024.217119_bib96","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s00432-011-1101-2","article-title":"Evaluation of oral chemotherapy with capecitabine and cyclophosphamide plus thalidomide and prednisone in prostate cancer patients","volume":"138","author":"Meng","year":"2012","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.canlet.2024.217119_bib97","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1186\/s12885-023-10780-y","article-title":"Activity and safety of KEES - an oral multi-drug chemo-hormonal metronomic combination regimen in metastatic castration-resistant prostate cancer","volume":"23","author":"Asowed","year":"2023","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.canlet.2024.217119_bib98","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s12032-014-0443-4","article-title":"Metronomic oral cyclophosphamide plus prednisone in docetaxel-pretreated patients with metastatic castration-resistant prostate cancer","volume":"32","author":"Barroso-Sousa","year":"2015","journal-title":"Med. Oncol."},{"issue":"24","key":"10.1016\/j.canlet.2024.217119_bib99","doi-asserted-by":"crossref","first-page":"3923","DOI":"10.1002\/cncr.28953","article-title":"Docetaxel plus oral metronomic cyclophosphamide: a phase II study with pharmacodynamic and pharmacogenetic analyses in castration-resistant prostate cancer patients","volume":"120","author":"Derosa","year":"2014","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.canlet.2024.217119_bib100","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1002\/cncr.11713","article-title":"Metronomic therapy with cyclophosphamide and dexamethasone for prostate carcinoma","volume":"98","author":"Glode","year":"2003","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.canlet.2024.217119_bib101","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1093\/jjco\/hyq178","article-title":"Retrospective analysis of an oral combination of dexamethasone, uracil plus tegafur and cyclophosphamide for hormone-refractory prostate cancer","volume":"41","author":"Hatano","year":"2011","journal-title":"Jpn. J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.canlet.2024.217119_bib102","first-page":"4317","article-title":"Metronomic oral cyclophosphamide prednisolone chemotherapy is an effective treatment for metastatic hormone-refractory prostate cancer after docetaxel failure","volume":"30","author":"Ladoire","year":"2010","journal-title":"Anticancer Res."},{"issue":"2","key":"10.1016\/j.canlet.2024.217119_bib103","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s12032-009-9218-8","article-title":"Clinical outcome of patients with docetaxel-resistant hormone-refractory prostate cancer treated with second-line cyclophosphamide-based metronomic chemotherapy","volume":"27","author":"Nelius","year":"2010","journal-title":"Med. Oncol."},{"issue":"8","key":"10.1016\/j.canlet.2024.217119_bib104","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1002\/cncr.11686","article-title":"Phase II trial of oral cyclophosphamide, prednisone, and diethylstilbestrol for androgen-independent prostate carcinoma","volume":"98","author":"Hellerstedt","year":"2003","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.canlet.2024.217119_bib105","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1038\/bjc.2011.411","article-title":"Continuous low-dose cyclophosphamide and methotrexate combined with celecoxib for patients with advanced cancer","volume":"105","author":"Khan","year":"2011","journal-title":"Br. J. Cancer"},{"issue":"5","key":"10.1016\/j.canlet.2024.217119_bib106","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyad017","article-title":"Ixazomib, oral metronomic cyclophosphamide, and dexamethasone for first-line treatment of multiple myeloma: a phase II Brown university oncology group study","volume":"28","author":"Pelcovits","year":"2023","journal-title":"Oncol."},{"issue":"5","key":"10.1016\/j.canlet.2024.217119_bib107","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1182\/blood-2011-02-338665","article-title":"Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation","volume":"118","author":"Morgan","year":"2011","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.canlet.2024.217119_bib108","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1182\/blood-2016-07-729236","article-title":"Phase 1\/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma","volume":"128","author":"Nijhof","year":"2016","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.canlet.2024.217119_bib109","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1080\/10428194.2020.1805111","article-title":"A phase II study of pomalidomide, daily oral cyclophosphamide, and dexamethasone in relapsed\/refractory multiple myeloma","volume":"61","author":"Van Oekelen","year":"2020","journal-title":"Leuk. Lymphoma"},{"issue":"3","key":"10.1016\/j.canlet.2024.217119_bib110","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1215\/15228517-2007-006","article-title":"Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults","volume":"9","author":"Kesari","year":"2007","journal-title":"Neuro Oncol."},{"issue":"5","key":"10.1016\/j.canlet.2024.217119_bib111","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1200\/JCO.2009.24.0143","volume":"28","author":"Wong","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.canlet.2024.217119_bib112","doi-asserted-by":"crossref","first-page":"451","DOI":"10.2217\/fon.12.196","article-title":"Safety and therapeutic effect of metronomic chemotherapy with cyclophosphamide and celecoxib in advanced breast cancer patients","volume":"9","author":"Perroud","year":"2013","journal-title":"Future Oncol."},{"key":"10.1016\/j.canlet.2024.217119_bib113","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.ejca.2019.07.018","article-title":"Programmed cell death 1 (PD-1) targeting in patients with advanced osteosarcomas: results from the MEMBROSA study","volume":"119","author":"Le Cesne","year":"2019","journal-title":"Eur. J. Cancer"},{"issue":"1","key":"10.1016\/j.canlet.2024.217119_bib114","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1001\/jamaoncol.2017.1617","article-title":"Use of PD-1 targeting, macrophage infiltration, and ido pathway activation in sarcomas: a phase 2 clinical trial","volume":"4","author":"Toulmonde","year":"2018","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.canlet.2024.217119_bib115","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ejca.2021.03.032","author":"Pasqualini","year":"2021","journal-title":"Eur. J. Cancer 150"},{"issue":"6","key":"10.1016\/j.canlet.2024.217119_bib116","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/s41591-019-0432-4","article-title":"Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial","volume":"25","author":"Voorwerk","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2024.217119_bib117","doi-asserted-by":"crossref","first-page":"4","DOI":"10.21037\/tgh.2017.12.09","article-title":"Limited activity of metronomic cyclophosphamide and pembrolizumab for soft tissue sarcomas","volume":"3","author":"Lien","year":"2018","journal-title":"Transl Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.canlet.2024.217119_bib118","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1001\/jamaoncol.2020.5945","article-title":"Efficacy and safety of pembrolizumab in combination with bevacizumab and oral metronomic cyclophosphamide in the treatment of recurrent ovarian cancer: a phase 2 nonrandomized clinical trial","volume":"7","author":"Zsiros","year":"2021","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.canlet.2024.217119_bib119","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.113525","article-title":"METRO-PD1: phase 1 study of nivolumab in combination with metronomic chemotherapy in children and adolescents with relapsing\/refractory solid tumors","volume":"198","author":"Andr\u00e9","year":"2024","journal-title":"Eur. J. Cancer"},{"issue":"5","key":"10.1016\/j.canlet.2024.217119_bib120","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/j.urology.2011.08.010","article-title":"Salvage therapy with oral metronomic cyclophosphamide and methotrexate for castration-refractory metastatic adenocarcinoma of the prostate resistant to docetaxel","volume":"78","author":"Gebbia","year":"2011","journal-title":"Urology"},{"issue":"6","key":"10.1016\/j.canlet.2024.217119_bib121","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1002\/(SICI)1097-0142(19960315)77:6<1144::AID-CNCR21>3.0.CO;2-0","article-title":"Phase II study of the oral cyclophosphamide and oral etoposide combination in hormone-refractory prostate carcinoma patients","volume":"77","author":"Maulard-Durdux","year":"1996","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.canlet.2024.217119_bib122","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1159\/000055296","article-title":"Oral combination of cyclophosphamide, uracil plus tegafur and estramustine for hormone-refractory prostate cancer","volume":"60","author":"Nishimura","year":"2001","journal-title":"Oncology"},{"issue":"6","key":"10.1016\/j.canlet.2024.217119_bib123","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1002\/(SICI)1097-0142(20000315)88:6<1438::AID-CNCR23>3.0.CO;2-O","article-title":"Oral estramustine and cyclophosphamide in patients with metastatic hormone refractory prostate carcinoma: a phase II study","volume":"88","author":"Bracarda","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.canlet.2024.217119_bib124","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.breast.2020.06.002","article-title":"Metronomic oral chemotherapy with cyclophosphamide plus capecitabine combined with trastuzumab (HEX) as first line therapy of HER-2 positive advanced breast cancer: a phase II trial of the Gruppo Oncologico Italia Meridionale (GOIM)","volume":"53","author":"Orlando","year":"2020","journal-title":"Breast"},{"issue":"3","key":"10.1016\/j.canlet.2024.217119_bib125","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1159\/000487630","article-title":"Metronomic chemotherapy for first-line treatment of metastatic triple-negative breast cancer: a phase II trial","volume":"13","author":"Montagna","year":"2018","journal-title":"Breast Care"},{"issue":"45","key":"10.1016\/j.canlet.2024.217119_bib126","doi-asserted-by":"crossref","first-page":"79527","DOI":"10.18632\/oncotarget.18539","article-title":"Whether low-dose metronomic oral cyclophosphamide improves the response to docetaxel in first-line treatment of non-triple-negative metastatic breast cancer","volume":"8","author":"Zhang","year":"2017","journal-title":"Oncotarget"},{"issue":"9","key":"10.1016\/j.canlet.2024.217119_bib127","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1001\/jamaoncol.2023.2150","volume":"9","author":"Munzone","year":"2023","journal-title":"JAMA Oncol."},{"issue":"28","key":"10.1016\/j.canlet.2024.217119_bib128","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.1200\/JCO.2015.65.6595","article-title":"Low-dose oral cyclophosphamide and methotrexate maintenance for hormone receptor-negative early breast cancer: international breast cancer study group trial 22-00","volume":"34","author":"Colleoni","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.canlet.2024.217119_bib129","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S1470-2045(18)30083-4","article-title":"Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force\/Breast Cancer Group","volume":"19","author":"Wildiers","year":"2018","journal-title":"Lancet Oncol."},{"issue":"22","key":"10.1016\/j.canlet.2024.217119_bib130","first-page":"3623","article-title":"Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients","volume":"24","author":"Bottini","year":"2006","journal-title":"J. Clin. Orthod."},{"issue":"2","key":"10.1016\/j.canlet.2024.217119_bib131","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.ygyno.2017.05.013","article-title":"Pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant, recurrent, pre-treated ovarian cancer - results of the PACORA-trial","volume":"146","author":"Dinkic","year":"2017","journal-title":"Gynecol. Oncol."},{"issue":"4","key":"10.1016\/j.canlet.2024.217119_bib132","first-page":"980","article-title":"Prolonged progression-free survival with maintenance metronomic oral cyclophosphamide and etoposide treatment in macroscopic residual disease or recurrent\/advanced stage ovarian cancer","volume":"19","author":"Uysal","year":"2014","journal-title":"J BUON"},{"issue":"2","key":"10.1016\/j.canlet.2024.217119_bib133","first-page":"167","article-title":"Triple combination of palliative oral metronomic chemotherapy in recurrent and metastatic epithelial ovarian cancer: a retrospective study","volume":"60","author":"Harsh","year":"2023","journal-title":"Indian J. Cancer"},{"issue":"5","key":"10.1016\/j.canlet.2024.217119_bib134","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1007\/s00262-019-02313-z","article-title":"Metronomic cyclophosphamide attenuates mTOR-mediated expansion of regulatory T cells, but does not impact clinical outcome in patients with metastatic renal cell cancer treated with everolimus","volume":"68","author":"Werter","year":"2019","journal-title":"Cancer Immunol. Immunother."},{"issue":"3","key":"10.1016\/j.canlet.2024.217119_bib135","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s00262-011-1106-3","article-title":"Metronomic cyclophosphamide treatment in metastasized breast cancer patients: immunological effects and clinical outcome","volume":"61","author":"Ge","year":"2012","journal-title":"Cancer Immunol. Immunother."},{"issue":"20","key":"10.1016\/j.canlet.2024.217119_bib136","doi-asserted-by":"crossref","first-page":"8843","DOI":"10.7314\/APJCP.2014.15.20.8843","article-title":"Oral cyclophosphamide and etoposide in treatment of malignant pleural mesothelioma","volume":"15","author":"Gunduz","year":"2014","journal-title":"Asian Pac. J. Cancer Prev. APJCP"},{"issue":"11","key":"10.1016\/j.canlet.2024.217119_bib137","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1016\/S1470-2045(19)30617-5","article-title":"Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomised, phase 3 trial","volume":"20","author":"Bisogno","year":"2019","journal-title":"Lancet Oncol."},{"issue":"12","key":"10.1016\/j.canlet.2024.217119_bib138","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1001\/jamaoncol.2023.4437","article-title":"Sustained survival benefit in recurrent medulloblastoma by a metronomic antiangiogenic regimen: a nonrandomized controlled trial","volume":"9","author":"Peyrl","year":"2023","journal-title":"JAMA Oncol."},{"issue":"8","key":"10.1016\/j.canlet.2024.217119_bib139","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1026529","article-title":"Survivin-targeted immunotherapy drives robust polyfunctional T cell generation and differentiation in advanced ovarian cancer patients","volume":"4","author":"Berinstein","year":"2015","journal-title":"OncoImmunology"},{"issue":"7","key":"10.1016\/j.canlet.2024.217119_bib140","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1158\/2326-6066.CIR-14-0027","article-title":"Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulation","volume":"2","author":"Lutz","year":"2014","journal-title":"Cancer Immunol. Res."},{"issue":"20","key":"10.1016\/j.canlet.2024.217119_bib141","first-page":"305","article-title":"The results with the addition of metronomic cyclophosphamide to palliative radiotherapy for the treatment of non-small cell lung carcinoma","volume":"3","author":"Revannasiddaiah","year":"2015","journal-title":"Ann. Transl. Med."},{"issue":"7","key":"10.1016\/j.canlet.2024.217119_bib142","doi-asserted-by":"crossref","first-page":"819","DOI":"10.3109\/02841869109091828","article-title":"Trofosfamide in non-Hodgkin\u2019s lymphoma. A phase II study","volume":"30","author":"Wist","year":"1991","journal-title":"Acta Oncol."},{"issue":"3","key":"10.1016\/j.canlet.2024.217119_bib143","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/S0959-8049(97)89029-6","article-title":"Trofosfamide as a salvage treatment with low toxicity in malignant lymphoma. A phase II study","volume":"33","author":"Helsing","year":"1997","journal-title":"Eur. J. Cancer"},{"issue":"10","key":"10.1016\/j.canlet.2024.217119_bib144","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1002\/cncr.11775","article-title":"Antiangiogenetic therapy with pioglitazone, rofecoxib, and metronomic trofosfamide in patients with advanced malignant vascular tumors","volume":"98","author":"Vogt","year":"2003","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.canlet.2024.217119_bib145","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1002\/cncr.20574","article-title":"Pioglitazone and rofecoxib combined with angiostatically scheduled trofosfamide in the treatment of far-advanced melanoma and soft tissue sarcoma","volume":"101","author":"Reichle","year":"2004","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.canlet.2024.217119_bib146","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1186\/s12885-018-4885-5","article-title":"Low-dose trofosfamide plus rituximab is an effective and safe treatment for diffuse large B-cell lymphoma of the elderly: a single center experience","volume":"18","author":"Schelker","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.canlet.2024.217119_bib147","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1177330","article-title":"All-oral low-dose chemotherapy TEPIP is effective and well-tolerated in patients with peripheral T-cell lymphoma","volume":"13","author":"Fante","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.canlet.2024.217119_bib148","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ejca.2019.10.016","article-title":"Randomised phase II trial of trofosfamide vs. doxorubicin in elderly patients with untreated metastatic soft-tissue sarcoma","volume":"124","author":"Hartmann","year":"2020","journal-title":"Eur. J. Cancer"},{"issue":"9","key":"10.1016\/j.canlet.2024.217119_bib149","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/s12032-019-1304-y","article-title":"Metronomic chemotherapy with cyclophosphamide plus low dose of corticosteroids in advanced castration-resistant prostate cancer across the era of taxanes and new hormonal drugs","volume":"36","author":"Calvani","year":"2019","journal-title":"Med. Oncol."},{"issue":"1","key":"10.1016\/j.canlet.2024.217119_bib150","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1186\/1471-2407-6-225","article-title":"Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer","volume":"6","author":"Orlando","year":"2006","journal-title":"BMC Cancer"},{"issue":"30","key":"10.1016\/j.canlet.2024.217119_bib151","doi-asserted-by":"crossref","first-page":"4899","DOI":"10.1200\/JCO.2008.17.4789","article-title":"Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer","volume":"26","author":"Dellapasqua","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.canlet.2024.217119_bib152","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/j.1524-4741.2012.01278.x","article-title":"Oral metronomic cyclophosphamide and methotrexate plus fulvestrant in advanced breast cancer patients: a mono-institutional case-cohort report","volume":"18","author":"Aurilio","year":"2012","journal-title":"Breast J."},{"issue":"19","key":"10.1016\/j.canlet.2024.217119_bib153","first-page":"284","article-title":"Metronomic methotrexate and cyclophosphamide after carboplatin included adjuvant chemotherapy in triple negative breast cancer: a phase III study","volume":"3","author":"Nasr","year":"2015","journal-title":"Ann. Transl. Med."},{"issue":"2","key":"10.1016\/j.canlet.2024.217119_bib154","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s00280-011-1728-3","article-title":"An all-oral combination of metronomic cyclophosphamide plus capecitabine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: a phase II study","volume":"69","author":"Wang","year":"2012","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"2","key":"10.1016\/j.canlet.2024.217119_bib155","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s00280-012-1826-x","article-title":"Metronomic oral combination chemotherapy with capecitabine and cyclophosphamide: a phase II study in patients with HER2-negative metastatic breast cancer","volume":"70","author":"Yoshimoto","year":"2012","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"4","key":"10.1016\/j.canlet.2024.217119_bib156","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.breast.2011.02.014","article-title":"Pegylated liposomal doxorubicin in combination with low-dose metronomic cyclophosphamide as preoperative treatment for patients with locally advanced breast cancer","volume":"20","author":"Dellapasqua","year":"2011","journal-title":"Breast"},{"issue":"3","key":"10.1016\/j.canlet.2024.217119_bib157","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1179\/joc.2010.22.3.201","article-title":"Oral metronomic chemo-hormonal-therapy of metastatic breast cancer with cyclophosphamide and megestrol acetate","volume":"22","author":"Licchetta","year":"2010","journal-title":"J. Chemother."},{"issue":"2","key":"10.1016\/j.canlet.2024.217119_bib158","doi-asserted-by":"crossref","first-page":"287","DOI":"10.4103\/0973-1482.154008","article-title":"Metronomic oral chemotherapy with old agents in patients with heavily treated metastatic breast cancer","volume":"11","author":"Mutlu","year":"2015","journal-title":"J. Cancer Res. Therapeut."},{"issue":"15_suppl","key":"10.1016\/j.canlet.2024.217119_bib159","article-title":"Phase II study of metronomic cyclophosphamide and temozolomide in platinum resistance ovarian cancer","volume":"33","author":"Bhattacharyya","year":"2015","journal-title":"J. Clin. Orthod."},{"issue":"23","key":"10.1016\/j.canlet.2024.217119_bib160","doi-asserted-by":"crossref","first-page":"4908","DOI":"10.1158\/1078-0432.CCR-23-1267","article-title":"Differential benefit of metronomic chemotherapy among triple-negative breast cancer subtypes treated in the IBCSG trial 22-00","volume":"29","author":"Joaquin Garcia","year":"2023","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.canlet.2024.217119_bib161","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/BF00570489","article-title":"Effect of body weight on the pharmacokinetics of cyclophosphamide in breast cancer patients","volume":"20","author":"Powis","year":"1987","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"3","key":"10.1016\/j.canlet.2024.217119_bib162","doi-asserted-by":"crossref","first-page":"272","DOI":"10.3390\/ph14030272","article-title":"Pharmacokinetics and pharmacogenetics of cyclophosphamide in a neonate and infant childhood cancer patient population","volume":"14","author":"Barnett","year":"2021","journal-title":"Pharmaceuticals"},{"issue":"1","key":"10.1016\/j.canlet.2024.217119_bib163","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1177\/0091270008325928","article-title":"Population pharmacokinetics of cyclophosphamide and metabolites in children with neuroblastoma: a report from the children's oncology group","volume":"49","author":"McCune","year":"2009","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.canlet.2024.217119_bib164","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.canlet.2018.01.050","article-title":"Immunogenic chemotherapy: dose and schedule dependence and combination with immunotherapy","volume":"419","author":"Wu","year":"2018","journal-title":"Cancer Lett"},{"issue":"1","key":"10.1016\/j.canlet.2024.217119_bib165","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1593\/neo.131910","article-title":"Intermittent metronomic drug schedule is essential for activating antitumor innate immunity and tumor xenograft regression","volume":"16","author":"Chen","year":"2014","journal-title":"Neoplasia"},{"issue":"1","key":"10.1016\/j.canlet.2024.217119_bib166","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1365-2125.1996.tb00153.x","article-title":"Cyclophosphamide pharmacokinetics in children","volume":"41","author":"Yule","year":"1996","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"4","key":"10.1016\/j.canlet.2024.217119_bib167","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1038\/bjc.2013.398","article-title":"VEGF-A polymorphisms predict progression-free survival among advanced castration-resistant prostate cancer patients treated with metronomic cyclophosphamide","volume":"109","author":"Orlandi","year":"2013","journal-title":"Br. J. Cancer"},{"issue":"2","key":"10.1016\/j.canlet.2024.217119_bib168","doi-asserted-by":"crossref","first-page":"115","DOI":"10.4103\/0019-509X.117031","article-title":"Association between baseline VEGF\/sVEGFR-2 and VEGF\/TSP-1 ratios and response to metronomic chemotherapy using cyclophosphamide and celecoxib in patients with advanced breast cancer","volume":"50","author":"Perroud","year":"2013","journal-title":"Indian J. Cancer"},{"issue":"3","key":"10.1016\/j.canlet.2024.217119_bib169","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/0277-5379(87)90075-7","article-title":"Cyclophosphamide versus ifosfamide: final report of a randomized phase II trial in adult soft tissue sarcomas","volume":"23","author":"Bramwell","year":"1987","journal-title":"Eur. J. Cancer Clin. Oncol."},{"issue":"1","key":"10.1016\/j.canlet.2024.217119_bib170","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/bjc.1983.2","article-title":"Isophosphoramide mustard, a metabolite of ifosfamide with activity against murine tumours comparable to cyclophosphamide","volume":"47","author":"Struck","year":"1983","journal-title":"Br. J. Cancer"}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383524005147?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383524005147?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T19:41:44Z","timestamp":1760816504000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383524005147"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":170,"alternative-id":["S0304383524005147"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2024.217119","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"\u201cCyclophosphamide and analogues; a matter of dose and schedule for dual anticancer activities\u201d","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2024.217119","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"217119"}}